Because VEGF-D testing may be a non-invasive alternative to lung biopsy for diagnosing LAM in women with cystic lung disease of unknown etiology [6], serum VEGF-D testing is now available for clinical use (see http://www.thelamfoundation.org/, VEGF-D TEST, VEGF-D quantification sample submission form). The gene discussed is VEGFD; the disease is lymphangioleiomyomatosis.